secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-09-03T12:05:06+00:00
Accession:  0001193125-26-381076
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals appoints Joseph Miller as CFO, effective September 2, 2026
-----------------------------------------------------------------------------

- Joseph M. Miller named CFO; previously CFO of Aurinia Pharmaceuticals (April 2020–March 2026).
- Initial annual base salary of $530,000; target bonus of 40% of base salary.
- Inducement option for 200,000 shares vesting over 4 years, 25% on first anniversary.
- Company nears NOVA-2 clinical trial readout and prepares for potential LB-102 launch in schizophrenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/0001193125-26-381076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526381076/d26110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-381076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer